Skip to main content
SpringerLink
Log in

Acute Coronary Syndrome

  • Chapter
  • First Online:
MGH Cardiology Board Review

  • 3348 Accesses

Abstract

Coronary artery disease is a major cause of mortality and morbidity in the United States and worldwide. In 2010, the American Heart Association reported that 17.6 million individuals in the United States had coronary artery disease and 8.5 million had a myocardial infarction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACC:

American College of Cardiology

ACE:

Angiotensin-converting enzyme

ACS:

Acute coronary syndrome

ADP:

Adenosine diphosphate

AHA:

American Heart Association

AKI:

Acute kidney injury

aPTT:

Activated partial thromboplastin time

ARB:

Angiotensin receptor blocker

AS:

Aortic stenosis

ASA:

Aspirin

AV:

Atrioventricular

BMS:

Bare metal stent

CABG:

Coronary artery bypass graft

CAD:

Coronary artery disease

CCS:

Canadian Cardiovascular Society

CHF:

Congestive heart failure

CP:

Chest pain

CPR:

Cardiopulmonary resuscitation

CVA:

Cerebrovascular accident

DAPT:

Dual antiplatelet therapy

DES:

Drug-eluting stent

DM:

Diabetes mellitus

ECG:

Electrocardiogram

GIB:

Gastrointestinal bleeding

GP IIb/IIIa:

Glycoprotein IIb/IIIa

HR:

Heart rate

HTN:

Hypertension

ICH:

Intracranial hemorrhage

IV:

Intravenous

LBBB:

Left bundle branch block

LDL-C:

Low density lipoprotein cholesterol

LMWH:

Low molecular weight heparin

LV:

Left ventricle

LVEF:

Left ventricular ejection fraction

MACE:

Major adverse cardiovascular events

MI:

Myocardial infarction

MR:

Mitral regurgitation

NSTEMI:

Non-ST-elevation myocardial infarction

NTG:

Nitroglycerin

OR:

Odds ratio

PAD:

Peripheral arterial disease

PCI:

Percutaneous coronary intervention

PMN:

Polymorphonuclear neutrophil

PO:

Per os

PTCA:

Percutaneous transluminal coronary angioplasty

RV:

Right ventricle

SBP:

Systolic blood pressure

SC:

Subcutaneous

STEMI:

ST-elevation myocardial infarction

TIA:

Transient ischemic attack

Tn:

Troponin

UA:

Unstable angina

UFH:

Unfraction heparin

VSR:

Ventricular septal rupture

VT:

Ventricular tachycardia

References

  1. Antman EM. ST-segment elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia: Saunders; 2008. p. 1087–110.

    Google Scholar 

  2. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable Angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1–157.

    Article  PubMed  Google Scholar 

  3. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey Jr DE, Ettinger SM, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920–59.

    Article  PubMed  Google Scholar 

  4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588–636.

    Article  PubMed  Google Scholar 

  5. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296–329.

    Article  PubMed  Google Scholar 

  6. American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions, O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.

    Article  PubMed  Google Scholar 

  7. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574–651.

    Article  PubMed  Google Scholar 

  8. Brady WJ, Erling B, Pollack M, Chan TC. Electrocardiographic manifestations: acute posterior wall myocardial infarction. J Emerg Med. 2001;20(4):391–401.

    Article  PubMed  CAS  Google Scholar 

  9. Roth A, Miller HI, Kaluski E, Keren G, Shargorodsky B, Krakover R, et al. Early thrombolytic therapy does not enhance the recovery of the right ventricle in patients with acute inferior myocardial infarction and predominant right ventricular involvement. Cardiology. 1990;77(1):40–9.

    Article  PubMed  CAS  Google Scholar 

  10. Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation. 1999;99(13):1671–7.

    Article  PubMed  CAS  Google Scholar 

  11. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011;124(2):136–45.

    Article  PubMed  CAS  Google Scholar 

  12. Keller T, Zeller T, Ojeda F, Tzikas S, Lillpopp L, Sinning C, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA. 2011;306(24):2684–93.

    Article  PubMed  CAS  Google Scholar 

  13. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–42.

    Article  PubMed  CAS  Google Scholar 

  14. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622–32.

    Article  PubMed  CAS  Google Scholar 

  15. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319(7):385–92.

    Google Scholar 

  16. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol. 1990;66(10):779–85.

    Google Scholar 

  17. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med. 1993;153(3):345–53.

    Article  PubMed  CAS  Google Scholar 

  18. Boden WE, O’Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338(25):1785–92.

    Article  PubMed  CAS  Google Scholar 

  19. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165–75.

    Article  PubMed  CAS  Google Scholar 

  20. Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA. 2009;302(9):947–54.

    Article  PubMed  CAS  Google Scholar 

  21. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

    Article  Google Scholar 

  22. CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930–42.

    Google Scholar 

  23. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  PubMed  CAS  Google Scholar 

  24. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  PubMed  CAS  Google Scholar 

  25. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin ­followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.

    Article  PubMed  CAS  Google Scholar 

  26. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  PubMed  CAS  Google Scholar 

  27. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339(7):436–43.

    Google Scholar 

  28. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338(21):1488–97.

    Google Scholar 

  29. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447–52.

    Article  PubMed  CAS  Google Scholar 

  30. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100(15):1593–601.

    Article  PubMed  CAS  Google Scholar 

  31. Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA. 2004;292(1):55–64.

    Article  PubMed  CAS  Google Scholar 

  32. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45–54.

    Article  PubMed  CAS  Google Scholar 

  33. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203–16.

    Article  PubMed  CAS  Google Scholar 

  34. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigator. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464–76.

    Google Scholar 

  35. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.

    Article  PubMed  CAS  Google Scholar 

  36. Bär FW, Verheugt FW, Col J, Materne P, Monassier JP, Geslin PG, et al. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation. 1992;86(1):131–7.

    Article  PubMed  Google Scholar 

  37. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625–34.

    Article  PubMed  CAS  Google Scholar 

  38. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358(6):557–67.

    Article  PubMed  CAS  Google Scholar 

  39. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–60.

    Google Scholar 

  40. Thrombolysis in Myocardial Ischemia (TIMI 3A) investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation. 1993;87(1):38–52.

    Google Scholar 

  41. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353(26):2758–68.

    Article  PubMed  CAS  Google Scholar 

  42. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367(9510):569–78.

    Google Scholar 

  43. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation ­myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294(10):1224–32.

    Article  PubMed  CAS  Google Scholar 

  44. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.

    Article  PubMed  CAS  Google Scholar 

  45. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–21.

    Article  PubMed  CAS  Google Scholar 

  46. Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119(14):1933–40.

    Article  PubMed  CAS  Google Scholar 

  47. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–30.

    Article  PubMed  CAS  Google Scholar 

  48. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354(14):1477–88.

    Article  PubMed  CAS  Google Scholar 

  49. Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol. 2003;42(8):1348–56.

    Article  PubMed  CAS  Google Scholar 

  50. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519–30.

    Article  PubMed  CAS  Google Scholar 

  51. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Jr EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.

    Article  PubMed  CAS  Google Scholar 

  52. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821–8.

    Google Scholar 

  53. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–906.

    Article  PubMed  CAS  Google Scholar 

  54. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.

    Article  PubMed  CAS  Google Scholar 

  55. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8.

    Article  PubMed  CAS  Google Scholar 

  56. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    Pradeep Natarajan MD (Clinical and Research Fellow)

  2. Harvard Medical School Interventional Cardiology, Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    Farouc A. Jaffer MD, PhD (Associate Professor of Medicine)

  3. Harvard Medical School, Boston, USA

    Marc S. Sabatine MD, MPH (Associate Professor of Medicine)

  4. TIMI Study Group, Cardiology Division, Departments of Medicine, Massachusetts General Hospital and Brigham & Women’s Hospital, Boston, MA, USA

    Marc S. Sabatine MD, MPH (Chairman)

Authors
  1. Pradeep Natarajan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farouc A. Jaffer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc S. Sabatine MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc S. Sabatine MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cardiology Division Yawkey Building 5B, Room 5850, Massachusetts General Hospital, Boston, Massachusetts, USA

    Hanna K. Gaggin

  2. Cardiology Division Yawkey Building, Suite 5984, Massachusetts General Hospital, Boston, Massachusetts, USA

    James L. Januzzi, Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Natarajan, P., Jaffer, F.A., Sabatine, M.S., Sabatine, M.S. (2014). Acute Coronary Syndrome. In: Gaggin, H., Januzzi, Jr., J. (eds) MGH Cardiology Board Review. Springer, London. https://doi.org/10.1007/978-1-4471-4483-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4483-0_3

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4482-3

  • Online ISBN: 978-1-4471-4483-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation